Introduction {#s1}
============

COPD is a common disease involving airflow limitations and chronic respiratory symptoms \[[@C1]\] and is the third-leading cause of death worldwide \[[@C2]\]. However, COPD is often detected only after the appearance of serious symptoms. There is widespread misdiagnosis of COPD because of insufficient recourse to spirometry testing \[[@C3]\]. The impact of COPD in women is significantly understudied.

Historically, COPD was considered a predominantly male disease. The latest national epidemiology report prepared by the Italian Society of General Practitioners showed that the prevalence of COPD in Italy increased by 30% from 2006 to 2016, from 2.3% to 3.0%, with a higher prevalence in men than women (3.6% *versus* 2.5%, respectively) \[[@C4]\]. In contrast, recent studies suggest the worldwide prevalence of COPD has been increasing more rapidly among women compared to men \[[@C5]--[@C7]\]. The changing epidemiology of COPD may be due to the increasing use of cigarettes among women, a major cause of this disease \[[@C8]\]. Indeed, women seem to be more vulnerable to cigarette smoke \[[@C9]\], potentially because men and women differ significantly in terms of airway anatomy, genetic susceptibility to airway damage and possibly also in their lung microbiome \[[@C10]\].

Despite the known increase in the prevalence of COPD among females, healthcare practitioners remain more likely to diagnose COPD among males than females \[[@C3]\]. In fact, women tend to have a higher self-reported prevalence of COPD, whereas the opposite is seen using administrative healthcare databases, suggesting potential gender bias \[[@C11]\]. Gender bias in clinical practice is a phenomenon whereby a physician is overly influenced by the patient\'s gender. This can impact diagnosis, follow-up care and pharmacological management. Gender bias is known to occur in several diseases, notably osteoporosis \[[@C12]\], which is more common among women, but also in cardiovascular disease, likely due to the different symptomatic presentation \[[@C13]\]. Gender differences in COPD management may be due several reasons, including difficulty in distinguishing symptoms of COPD from those of asthma, of which the latter is known to be more common in women \[[@C14]\]. Gender differences in COPD diagnosis might also be related to the difference in clinical presentation of symptoms among women \[[@C3], [@C15]\]. Irrespective of the reason, COPD among women continues to be more commonly under-diagnosed or misdiagnosed in comparison to men, potentially also because women are less likely to have received spirometry tests \[[@C16]\]. Women are therefore less likely to be treated appropriately for COPD \[[@C17], [@C18]\]. It is currently not clear whether or how gender differences could influence the overall quality of care (QOC) among COPD patients. Other important aspects of the COPD management include the implementation of recommended preventative measures (*e.g.* noting and recording smoking habits, administration of vaccines) and recommendations on the therapeutic process (*e.g.* promoting high adherence to COPD medications). In general, data on whether women and men receive differential COPD care are somewhat limited \[[@C19]\]. It is also not clear how potential gender differences in clinical care among COPD patients affects clinical outcomes such as hospitalisation.

To date, various educational programmes for clinicians have been shown to be valid tools to improve the QOC of COPD patients in several countries \[[@C19]--[@C21]\]. In Italy, F[errara]{.smallcaps} *et al*. \[[@C22]\] evaluated the effectiveness of an educational programme promoting best practices for the management of COPD in primary care based on clinical audits and continuous remote education. However, this study did not shed light on potential gender differences in COPD management, including how educational intervention would impact any gender differences seen. Identifying gender disparities in COPD management is crucial to assess the need for tailored educational programmes that can improve QOC in primary care. The aim of the present study was therefore to evaluate gender differences in the management of COPD outpatients, in terms of QOC, and measure whether any such differences changed after the implementation of educational interventions in a Southern Italian general practice setting.

Methods {#s2}
=======

Study setting and data source {#s2a}
-----------------------------

The study was conducted in a primary care setting. Electronic medical records (EMRs) containing anonymised patient data recorded by general practitioners (GPs) during routine clinical practice were used. Overall, 33 Sicilian GPs contributed data from 46 326 patients, including demographic information, diagnoses coded in International Classification of Diseases, 9th Edition, with clinical modifications (ICD-9 CM), drugs prescribed coded using the Anatomic Therapeutic and Chemical classification (ATC) coding system and lifestyle information such smoking habits. Other information, such as body mass index (BMI), administration of influenza vaccine and *Streptococcus pneumoniae* vaccine were also recorded.

Study design and participants {#s2b}
-----------------------------

A prospective cohort study design was employed. Patients with COPD were identified from the EMRs between 2013 and 2015 using the following ICD-9 CM codes: 496 and subcodes (chronic airway obstruction, not elsewhere classified) and 491.2 and subcodes (obstructive chronic bronchitis). Suspected diagnoses of COPD were thereafter validated by GPs through clinical revaluation and, whenever possible, spirometry. The first date at which a COPD patient visited the GP during the study period was considered the cohort entry date (baseline).

Educational intervention {#s2c}
------------------------

An educational intervention was addressed to all GPs who contributed data to the study \[[@C22]\]. The intervention consisted of planned continuing professional education seminars and continuous remote education on COPD diagnosis and management. Further information is provided in [supplementary box 1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00279-2020.figures-only#fig-data-supplementary-materials).

COPD QOC indicators {#s2d}
-------------------

Twelve indicators of good QOC reflecting best practices for COPD management were developed based on the COPD Global Initiative for Chronic Obstructive Lung Disease guidelines \[[@C23]\]. These QOC indicators were developed jointly by respiratory specialists, GPs and clinical pharmacologists. The indicators consisted of three macro-categories: COPD diagnostic processes, measures to prevent complications of COPD (hereafter referred to as preventative measures) and therapeutic processes. The full list of QOC indicators along with the rationale behind them is available in [supplementary table 1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00279-2020.figures-only#fig-data-supplementary-materials). The 12 QOC indicators were considered singly to provide the greatest possible granular detail on COPD management, grouped together into a composite variable as a macro-category to provide an overview of the three general clinical aspects of COPD management and pooled altogether as a composite variable consisting of all three macro-categories to provide an overview of COPD management in the most general terms possible.

###### 

Demographic, clinical and therapeutic characteristics at baseline of patients with a COPD diagnosis included in the cohort

                                                                                       **Baseline**       **p-value**^\#^   
  --------------------------------------------------------------------------------- ------------------- ------------------- --------
  **Age years**                                                                      74.0 (66.0--81.0)   74.0 (64.0--82.0)    0.39
  **Age categories (years)**                                                                                                
   \<45                                                                                  19 (2.0)            10 (1.9)         0.80
   45--54                                                                                39 (4.2)            50 (9.3)        \<0.05
   55--64                                                                               141 (15.2)           80 (14.9)        0.88
   65--74                                                                               274 (29.5)          132 (24.6)       \<0.05
   75--84                                                                               332 (35.8)          185 (34.5)        0.61
   ≥85                                                                                  124 (13.4)           79 (14.7)        0.46
  **Last smoking status prior to cohort entry**                                                                             
   Smoker                                                                               286 (30.8)          120 (22.4)       \<0.05
   Former smoker^¶^                                                                     326 (35.1)           47 (8.8)        \<0.05
   Never-smoker                                                                         135 (14.5)          208 (38.8)       \<0.05
   Unknown                                                                              182 (19.6)          161 (30.0)       \<0.05
  **Last BMI status prior to cohort entry**                                                                                 
   Underweight (\<18.5)                                                                   3 (0.3)             6 (1.1)         0.08
   Normal weight (18.5--24.9)                                                            96 (10.4)           73 (13.6)        0.06
   Overweight (25.0--29.9)                                                              282 (30.4)           94 (17.5)       \<0.05
   Obese (≥30.0)                                                                        344 (37.1)          212 (39.6)        0.35
   Unknown                                                                              202 (21.8)          151 (28.2)       \<0.05
  **Hospital admissions for COPD exacerbation in the year prior to cohort entry**        25 (2.7)             6 (1.1)         0.04
  **Comorbidities any time prior to cohort entry^+^**                                                                       
   Cardiovascular disorders                                                                                                 
    Hypertension                                                                        666 (71.8)          415 (77.4)       \<0.05
    Heart failure                                                                       133 (14.3)           74 (13.8)        0.77
    Arrhythmia                                                                           41 (4.4)            28 (5.2)         0.62
    Atrial fibrillation                                                                  96 (10.3)           50 (9.3)         0.52
    Ischaemic heart disease                                                             199 (21.5)           66 (12.3)       \<0.05
    Cerebrovascular disease                                                             264 (28.5)          126 (23.5)       \<0.05
   Metabolic diseases                                                                                                       
    Diabetes mellitus                                                                   281 (30.3)          138 (25.7)        0.06
    Osteoporosis                                                                         62 (6.7)           207 (38.6)       \<0.05
    Hyperlipidaemia                                                                     386 (41.6)          228 (42.5)        0.73
    Thyroid disorders                                                                   127 (13.7)          188 (35.0)       \<0.05
   Nervous system disorders                                                                                                 
    Anxiety                                                                              63 (6.8)            55 (10.3)       \<0.05
    Schizophrenic disorder                                                                7 (0.7)             5 (0.9)         0.71
    Depression                                                                           43 (4.6)            57 (10.6)       \<0.05
    Dementia                                                                             39 (4.2)            22 (4.1)         0.22
    Parkinson\'s disease                                                                 26 (2.8)            14 (2.6)         0.82
   Gastrointestinal disorders                                                                                               
    GORD                                                                                190 (20.5)          131 (24.4)        0.08
    History of peptic ulcer                                                              47 (5.1)            19 (3.5)         0.17
   Rheumatological diseases                                                                                                 
    Arthritis and arthrosis                                                             496 (53.5)          414 (77.2)       \<0.05
    Gout                                                                                150 (16.2)           82 (15.3)        0.65
   Diseases affecting sense organs                                                                                          
    Cataracts                                                                           151 (16.3)           86 (16.0)        0.90
    Retinopathy                                                                          70 (7.5)            38 (7.1)         0.74
   Other disorders                                                                                                          
    Liver disease                                                                       131 (14.1)           56 (10.4)        0.04
    Chronic kidney disease                                                              175 (18.9)           91 (16.9)        0.36
   Charlson index score                                                                                                     
    0                                                                                    23 (2.4)            10 (1.8)         0.44
    1--2                                                                                469 (50.6)          307 (57.3)       \<0.05
    ≥3                                                                                  435 (46.9)          219 (40.8)       \<0.05
  **Respiratory drugs used in the year prior to cohort entry^+^**                                                           
   Single drugs with or without concomitant drugs                                                                           
    ICS                                                                                 260 (28.0)          164 (30.6)        0.30
    SABA                                                                                 65 (7.0)            28 (5.2)         0.17
    SAMA                                                                                 20 (2.1)             6 (1.1)         0.15
    LABA                                                                                103 (11.1)           42 (7.8)         0.04
    LAMA                                                                                284 (30.6)          115 (21.4)       \<0.05
    Xanthines                                                                            70 (7.5)            26 (4.8)        \<0.05
    Leukotriene receptor antagonists                                                     19 (2.0)            15 (2.8)         0.35
    Chromones                                                                             4 (0.4)             4 (0.7)         0.47
    Mucolytic agents                                                                    154 (16.6)           72 (13.4)        0.10
   Specific combinations: fixed or nonfixed combinations                                                                    
    SABA+ICS                                                                                                                
     Concomitant use, nonfixed combination                                               18 (1.9)             8 (1.5)         0.53
    LABA+ICS                                                                                                                
     Fixed combination                                                                  287 (30.9)          159 (29.6)        0.60
     Concomitant use, nonfixed combination                                               21 (2.3)            10 (1.8)         0.60
    LAMA+ICS nonfixed combination                                                        74 (7.9)            27 (5.0)        \<0.05
    LABA+LAMA                                                                                                               
   *  *Concomitant use, nonfixed combination                                             51 (5.5)            19 (3.5)         0.09
    LABA+LAMA+ICS                                                                                                           
   *  *Concomitant use, nonfixed combination                                            126 (13.6)           45 (8.4)        \<0.05
   Median number of respiratory drugs                                                   2.0 (1--3)          2.0 (1--3)        0.03
  **Antibiotic use prior to cohort entry^+^**                                                                               
   Penicillins                                                                          279 (30.1)          156 (29.1)        0.69
    Amoxicillin and β-lactamase inhibitor                                               214 (23.0)          120 (22.4)        0.76
    Amoxicillin                                                                          53 (5.7)            27 (5.0)         0.58
  *  *Other penicillins                                                                  12 (1.3)             9 (1.7)         0.55
   Cephalosporins (I, II, III and IV generations)                                       239 (25.8)          153 (28.5)        0.25
    Ceftriaxone                                                                         141 (15.2)           94 (17.5)        0.24
    Cefixime                                                                             32 (3.4)            20 (3.7)         0.78
    Other cephalosporins                                                                 66 (7.1)            39 (7.2)         0.91
   Macrolides                                                                           140 (15.1)           93 (17.3)        0.25
    Clarithromycin                                                                       77 (8.3)            52 (9.7)         0.36
    Azithromycin                                                                         40 (4.3)            27 (5.0)         0.52
    Other macrolides                                                                     23 (2.4)            14 (2.6)         0.88
   Fluoroquinolones                                                                     380 (41.0)          189 (35.2)       \<0.05
    Levofloxacin                                                                        244 (26.3)          101 (18.8)       \<0.05
    Ciprofloxacin                                                                        95 (10.2)           61 (11.3)        0.50
    Other fluoroquinolones                                                               41 (4.4)            27 (5.0)         0.59
   Any antibiotic                                                                       582 (62.8)          325 (60.6)        0.41
   Median number of different antibiotic drugs                                          2.0 (1--2)          1.0 (1--2)        0.21
  **Concomitant drug use in the year prior to cohort entry^+^**                                                             
   Cardiovascular drugs                                                                                                     
    ACEIs                                                                               327 (35.3)          161 (30.0)       \<0.05
    ARBs                                                                                193 (20.8)          104 (19.4)        0.51
    Calcium channel blockers                                                            226 (24.4)          130 (24.2)        0.95
    Diuretics                                                                           325 (35.0)          209 (39.0)        0.13
    Beta blockers                                                                       208 (22.4)          143 (26.7)        0.06
    Other antihypertensives                                                              59 (6.3)            50 (9.3)        \<0.05
    Digitalis glycosides                                                                 44 (4.7)            21 (3.9)         0.45
    Vasodilators                                                                         91 (9.8)            41 (7.6)         0.16
    Anti-arrythmics of classes I and III                                                 40 (4.3)            15 (2.8)         0.14
    Anti-thrombotics                                                                    520 (56.1)          264 (49.2)       \<0.05
   Drugs for metabolic disease                                                                                              
    Antidiabetics                                                                       255 (27.5)          118 (22.0)       \<0.05
    Antilipidaemic drugs                                                                369 (39.8)          178 (33.2)       \<0.05
    Anti-osteoporosis drugs                                                              11 (1.2)            96 (17.9)       \<0.05
   Drugs acting on the immune system                                                                                        
    Systemic corticosteroids                                                            264 (28.5)          179 (33.4)       \<0.05
   Analgesics                                                                                                               
    NSAIDs                                                                              385 (41.5)          264 (49.2)       \<0.05
    Opioids                                                                             107 (11.5)          100 (18.6)       \<0.05
   Psychiatric drugs                                                                                                        
    Antidepressants                                                                     114 (12.3)          112 (20.9)       \<0.05
    BDZs                                                                                 58 (6.2)            53 (9.8)        \<0.05
   Other drugs                                                                                                              
    Drugs for peptic ulcer and GORD                                                     609 (65.7)          379 (70.7)       \<0.05
   Median number of concomitant drugs                                                    9 (6--14)          10 (6--15)       \<0.05

Data are presented as n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; ICS: inhaled corticosteroids; SABA: short-acting β-agonist; SAMA: short-acting muscarinic antagonist; LABA: long-acting β-agonist; LAMA: long-acting muscarinic antagonist; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; NSAIDs: nonsteroidal anti-inflammatory drugs; BDZs: benzodiazepines; GORD: gastro-oesophageal reflux disease. ^\#^: p-values were calculated using Chi-squared test or Fisher\'s exact test when the expected frequencies were \<5. A Mann--Whitney U-test was used for median values. ^¶^: stopped smoking for at least 1 year. ^+^: not mutually exclusive.

Covariates {#s2e}
----------

The covariates included in the study are found in [supplementary box 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00279-2020.figures-only#fig-data-supplementary-materials) and [supplementary tables 1 and 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00279-2020.figures-only#fig-data-supplementary-materials).

###### 

Gender-specific hospital admissions among COPD patients at baseline and at 24 months

  **Type of hospital admission**                **Males**    **Females**                                
  -------------------------------------------- ------------ ------------- ----- ----------- ----------- -----
  **Any diagnosis**                             160 (25.4)   128 (20.3)    5.1   74 (21.6)   56 (16.4)   5.2
  **COPD as primary or secondary diagnosis**     47 (7.5)     30 (4.8)     2.7   20 (5.8)     9 (2.6)    3.2
  **COPD as primary diagnosis**                  6 (1.0)        0 (0)      1.0    4 (1.2)     1 (0.3)    0.8

Outcomes {#s2f}
--------

Hospitalisation was identified as a clinical outcome, identified through patient-level deterministic linkage with hospital discharge records from Sicilian claims databases. Hospitalisation was categorised as all-cause hospitalisation, hospitalisation for COPD as a primary or secondary diagnosis and hospitalisation for COPD as a primary diagnosis (*i.e.* for an exacerbation of COPD). Italian claims records have been described in detail elsewhere \[[@C24]\]. Patient informed consent was specifically requested for data linkage.

Data analysis {#s2g}
-------------

Descriptive statistics were used to describe baseline patient characteristics. Among patients evaluated both at baseline and after 12 or 24 months, Hierarchical Generalised Linear Models (HGLMs) were fitted to estimate the frequencies of the 12 QOC indicators at such time points, in males compared to females. HGLMs account for clustering due to GPs (multilevel structure), assuming binomial distribution of data and the logistic link function, including follow-up time, gender and time-by-gender as categorical covariates, along with a random intercept. The odds ratios (ORs) of having a QOC indicator were derived from HGLMs (males as comparator group), along with 95% confidence intervals (CIs). A forest plot of the estimated ORs, stratified by their macro-categories, at baseline and over time was produced. Analyses were repeated for QOC macro-categories and for a composite indicator composed of all the QOC indicators. A subanalysis was performed, stratifying gender-specific analyses by smoking habits: current, former, never-smokers and those with unknown smoking status.

All analyses were performed using SAS Software, Release 9.4 (SAS Institute, Cary, NC, USA). All plots were created by R Core Team (2018). R: A language and environment for statistical computing (version 3.5.3).

Ethics statement {#s2h}
----------------

The Ethical Committee of Academic Hospital "G. Martino" of Messina approved the study (protocol no. 39-12, September 14, 2012). Informed consent to use patient data was obtained from all patients participating in the study.

Results {#s3}
=======

Cohort characteristics {#s3a}
----------------------

Of 46 326 persons registered in the practices of participating GPs, 1463 (3.1%) COPD patients were identified; of these, approximately a third (n=536) were women ([table 1](#TB1){ref-type="table"}). The median age (1st to 3rd quartile) was similar between males and females, at 74 (66--81) *versus* 74 (64--82) years, respectively. Approximately 65.9% (n=612) and 31.2% (n=167) of males and females respectively were current or former smokers. Overall, smoking status was known for 80% of males (n=747) and 70% of females (n=375), respectively. In terms of burden of disease, males were slightly more likely to have a Charlson index score of 3 or more compared to females (46.9% males *versus* 40.8% females; p\<0.05). Concerning the use of specific drugs, the most commonly used respiratory drugs among both sexes were long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICSs) as a fixed combination. However, twice as many males were treated with LABAs, long-acting acting muscarinic agents (LAMAs) and ICSs concomitantly compared to females (14% *versus* 8%). Almost two-thirds of males or females were treated with antibiotics, with no significant differences between sexes. Among antibiotics, fluoroquinolones were most commonly prescribed in both sexes (41.0% in males *versus* 35.2% in females; p\<0.05). The median number of distinct drugs as the presence of different ATC codes (1st to 3rd quartile) prescribed in the year prior to cohort entry was similar for both sexes: 9 (6--14) for males *versus* 10 (6--15) for females. GP clinical performance based on the QOC indicator frequencies was generally better among males ([figure 1](#F1){ref-type="fig"}), remaining consistent at 12 and 24 months ([supplementary figure 1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00279-2020.figures-only#fig-data-supplementary-materials)).

![Gender differences concerning quality of care indicators at baseline. BMI: body mass index; ICS: inhaled corticosteroid; LABA: long-acting β-agonist; LAMA: long-acting muscarinic agonist.](00279-2020.01){#F1}

Changes of QOC indicators at baseline and over time {#s3b}
---------------------------------------------------

The odds of having an individual QOC indicator reflecting best practice 24 months after the educational programmes were generally not different to the baseline assessment, where men were generally more likely to have good QOC than women ([figure 2](#F2){ref-type="fig"}). At baseline, the likelihood of being highly adherent to LABA and/or LAMA therapy (±ICSs), of having smoking status recorded and of non-occasional use of COPD medication was 53%, 49% and 42% lower among women, respectively. At 24 months, the gender disparity observed at baseline disappeared for two indicators of QOC at 24 months: having patient BMI recorded any time and the non-occasional use of COPD drugs. Worsening gender disparity was observed for two individual QOC indicators (*i.e.* the administration of the influenza vaccination (OR: 0.84; 95% CI: 0.64--1.08 at baseline *versus* OR: 0.66; 95% CI: 0.50--0.87 at 24 months) and use of any COPD drugs in the year prior to data collection (OR: 1.01; 95% CI: 0.79--1.30 at baseline *versus* OR: 0.77; 95% CI: 0.60--1.00 at 24 months)). Considering gender differences in the composite QOC indicators by macro-categories, there was a reduction in gender disparity from baseline to 24 months for diagnostic processes and therapeutic processes, but no improvement for preventative measures, with the latter favouring men more markedly at 24 months: OR: 0.76; 95% CI: 0.58--0.99 at baseline and OR: 0.64; 95% CI: 0.49--0.84 at 24 months ([figure 3](#F3){ref-type="fig"}). Results from the comparison of the overall QOC indicator suggested that odds of receiving good QOC in general at baseline were significantly higher in men than women (OR: 0.74; 95% CI: 0.57--0.96) becoming nonsignificant at 24 months (OR: 0.96; 95% CI: 0.72--1.29). Concerning clinical outcomes among COPD patients, a decrease in the trend of hospitalisations over time was observed. The reduction in hospitalisations at 24 months compared to baseline was similar for men and women ([table 2](#TB2){ref-type="table"}).

![Gender differences in individual quality of care indicators among COPD patients before and after the educational intervention. BMI: body mass index; ICS: inhaled corticosteroid; LABA: long-acting β-agonist; LAMA: long-acting muscarinic agonist.](00279-2020.02){#F2}

![Gender differences in composite quality of care indicators by macro-categories, among COPD patients before and after the educational intervention. Data at a) baseline, b) 12 months and c) 24 months.](00279-2020.03){#F3}

Subgroup analysis {#s3c}
-----------------

The statistically significant gender disparity in QOC observed at baseline in the whole cohort of COPD patients was generally not seen when restricted to different subgroups based on smoking habits, although a trend favouring men for most of macro-categories analysed was observed. Interestingly, the analysis on current and former smokers together showed a borderline significant trend favouring men for the preventative measure macro-category at baseline which become clearly nonsignificant at 24 months ([figure 4](#F4){ref-type="fig"}). Considering the subgroup analysis on single QOC indicators, the only indicator indicating a statistically significant gender disparity at baseline was the non-occasional use of LABAs and/or LAMAs (±ICSs) among current smokers at baseline, which were more common among men; this became nonsignificant at 24 months ([supplementary figures 2--5](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00279-2020.figures-only#fig-data-supplementary-materials)).

![Gender differences in individual quality of care indicators among COPD patients before and after the educational intervention, stratified by smoking status. Data for a) never-smokers, b) current and former smokers, and c) unknown smoking status.](00279-2020.04){#F4}

Discussion {#s4}
==========

To our knowledge, the present study is the first to evaluate gender disparity in QOC among COPD patients in a primary care setting in Italy. There is very limited information on gender differences in COPD management in a primary setting. For example, a recently published study in Sweden described comorbidities and healthcare utilisation among males and females with COPD, as well the frequency of hospitalisation, which were generally similar to the present study \[[@C25]\]. However, there was no information on the QOC in terms of adherence to COPD therapy, administrations of vaccinations and use of spirometry tests. Our findings suggest that several gender differences exist in the QOC of COPD patients but that these can be partly mitigated through continuing professional education. Perhaps one of the most important findings of the present study is that the borderline gender disparity in the use of spirometry tests in the year prior to cohort entry became markedly nonsignificant at 24 months. This is important as spirometry is crucial to diagnose and monitor COPD \[[@C11]\]. In other words, on comparing the use of spirometry tests any time between males and females (*i.e.* a historical overview of gender bias using the earliest to the latest available EMRs), it emerged that the gender bias favouring men did not improve after the intervention. However, the effect of the educational programme could be observed in the QOC indicator indicative of recent behavioural changes in COPD diagnosis, showing that the borderline gender disparity in the use of spirometry tests at baseline improved, becoming more markedly nonsignificant at 24 months. Similarly, considering QOC indicators by diagnostic process macro-category, the overall gender bias favouring men which was borderline significant became nonsignificant at 24 months. Other important findings concerned gender disparity in QOC at baseline in terms of pharmacological therapy (*i.e.* non-occasional use of LABAs and/or LAMAs with or without ICSs and high adherence to LABA and/or LAMA therapy with or without ICSs). The gender disparity for the former indicator but not for high adherence to COPD medications disappeared after the implementation of the educational programme, where a persistence in gender disparity favouring men was observed 24 months after the intervention. Overall, considering all QOC indicators (*i.e.* a composite of the three macro-categories together), a gender disparity in QOC favouring males in the whole COPD cohort was seen at baseline but this disappeared after the educational programme at 24 months. The gender differences in QOC observed at baseline and beyond are unlikely to be explained by a different burden of treatment or disease of our cohort of COPD patients, as both men and women had a similar disease burden and intensity of pharmacological treatment at baseline. The driver behind the gender difference observed is therefore more likely to be physician attitudes and knowledge concerning COPD. Indeed, even when symptoms are similar, primary care clinicians still diagnose COPD more commonly in males \[[@C26]\]. The potentially subjective basis of COPD diagnoses was highlighted in a study conducted in Spain, which showed that the gender differences in diagnosing COPD disappeared after clinicians based their diagnosis on spirometry results, highlighting the importance of spirometry to improve COPD diagnosis \[[@C27]\]. Interestingly, the gender disparities in QOC at baseline and at 24 months did not co-occur with a gender difference in hospitalisations.

Our study has several strengths and limitations. We used data from EMRs, which are a rich source of real-world data. Indeed, in addition to shedding light on study-specific objectives, we were also able to describe patterns of drug utilisation in COPD patients that are not in line with GOLD guidelines \[[@C1]\]. For example, the use of ICS as monotherapy is not in line with the GOLD guidelines; similarly, the use of leukotriene receptor antagonists and chromones among COPD patients is not recommended, as these drugs are predominately used for the treatment of asthma. In a real-world setting, some degree of inappropriate medication use is to be expected, as indeed is actually seen. We consider that the value of observational studies such as the present study is precisely that we can closely examine drug use and other clinical details as they actually occur in clinical practice in order to identify areas for improvement. The main advantage of this data source in studying a disease such as COPD is the wealth of information on patient lifestyle and medical history such as smoking status, BMI and vaccinations. The longitudinal EMR data gave us 24 months of observation time, allowing us to measure the effect of the educational intervention in the short- and medium-term. The QOC indicators were developed to provide global overview of COPD management, encompassing various aspects of care. Analysing QOC at a very granular level and also using composite QOC indicators allowed us to identify potential clinical drivers of disparity in QOC, which can be potential targets to improve clinical management, without losing sight of the overall QOC.

However, our study also has some limitations. Primary care databases can have problems concerning COPD misclassification, for example misdiagnosing COPD as asthma. Whenever possible, validation of COPD diagnoses was carried out through spirometry tests. However, the validation of the COPD diagnosis was not as robust as it would have been in a clinical trial, but was limited to the level of diagnostic certainty that is available in a real-world primary care setting. The level of certainty underlying the COPD diagnoses in the present study is similar to that seen in similar EMR-based studies, such as those carried out using The Health Improvement Database \[[@C28]\], Health Search Database \[[@C29]\] and the Spanish Database for Pharmacoepidemiological Research in Primary Care \[[@C30]\]. The completeness of smoking data is contingent on the quality of GP data recording; indeed, 19.6% and 30.0% of males and females respectively had an unknown smoking status. For former smokers, we did not have information on the time elapsed since smoking cessation, although this is relevant information, especially concerning potentially preventable hospitalisation \[[@C31]\]. The higher number of female rather than male never-smokers was unexpected, but is in line with other studies \[[@C18], [@C32]\]. Female nonsmokers affected by other respiratory diseases could be theoretically be misclassified as COPD patients. However, almost two-thirds of females categorised as never-smokers had their COPD diagnosis confirmed by a spirometry test. The overall never-smoker proportion of 23% is in line with global estimates of never-smoker COPD patients, showing that 25--45% of COPD patients were never-smokers \[[@C33]\]. Regarding the preventative measure-related QOC, the use of vaccinations may also be under-reported in the EMRs, because GPs are already required to enter data in a vaccine registry, and may not re-enter the same data in the EMRs. It is therefore important to interpret these results with caution. Another limitation that could have negatively influenced the effect of the intervention on preventative measures is that the changes in clinical practice observed may be influenced by external factors that could not be adjusted for. One notable example is the excessive media attention in Italy given to some cases of very serious adverse drug reactions potentially attributable to the influenza vaccination during the study period \[[@C34]\]. It is possible that to improve QOC concerning preventative measures, the intervention may need to be longer and more intensive. Finally, results from the present study in a Southern Italian setting cannot be generalised to the management of COPD in Italy, as patient characteristics and clinical practice is known to vary from North to Southern Italy \[[@C4]\]. However, findings are likely to be generalisable to other Southern Italian settings.

Conclusion {#s4a}
----------

Specific QOC indicators in a cohort of COPD patients in a Southern Italian general practice setting showed gender disparities favouring men in several aspects of COPD management, notably high adherence to COPD medications and non-occasional use of COPD medications. However, the global gender disparities seen at baseline disappeared at 24 months, suggesting that educational interventions often but not always reduced the gender disparity in QOC. Providing continuing professional education on gender difference in COPD may additionally reduce disparity in QOC.
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